Sinco Pharmaceuticals Holdings Limited

6833

KYG8154Y1052

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 04:08:09 2024-05-16 EDT			5-day change	1st Jan Change
0.237 ^HKD	-0.42%		+2.60%	-1.25%

03-27	Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments	MT
03-26	Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	CI

Sinco Pharmaceuticals Holdings Limited completed the acquisition of Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun.

December 30, 2022

Sinco Pharmaceuticals Holdings Limited (SEHK:6833) entered into a letter of interest to acquire Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun on January 20, 2022. Sinco Pharmaceuticals Holdings Limited (SEHK:6833) entered into equity transfer agreement to acquire Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun on March 22, 2022.

Sinco Pharmaceuticals Holdings Limited (SEHK:6833) completed the acquisition of Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun on December 31, 2022.

Latest news about Sinco Pharmaceuticals Holdings Limited

Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments	03-26	MT
Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	03-26	CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director	03-26	CI
Sinco Pharmaceuticals Warns of Lower 2023 Profit	03-13	MT
Sinco Pharmaceuticals Holdings Limited Provides Consolidated Earning Guidance for the Year Ended 31 December 2023	03-13	CI
Sinco Pharmaceuticals Holdings Limited(SEHK:6833) dropped from S&P Global BMI Index	23-09-18	CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Sinco Pharmaceuticals Warns of 68% Drop in H1 Profit	23-08-16	MT
Sinco Pharmaceuticals Holdings Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023	23-08-16	CI
Sinco Pharma Taps Moore Advisory Services for Internal Control Review	23-05-01	MT
Sinco Pharmaceuticals Co-CEO Resigns; Shares Slip 3%	23-03-30	MT
Sinco Pharmaceuticals Holdings Limited Announces Final Dividend for the Year Ended 31 December 2022, Payable on June 15, 2023	23-03-29	CI
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Sinco Pharmaceuticals Holdings Limited Announces Chief Executive Officer Changes	23-03-29	CI
Sinco Pharmaceuticals Holdings Limited Appoints Lei Shifeng as Executive Director, with Effect from 29 March 2023	23-03-29	CI
Sinco Pharmaceuticals Expects 50% Drop in 2022 Profit; Shares Slip 4%	23-03-16	MT
Sinco Pharmaceuticals Holdings Limited Provides Group Earnings Guidance for the Year Ended 31 December 2022	23-03-15	CI
Sinco Pharmaceuticals Holdings Limited completed the acquisition of Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun.	22-12-30	CI
Sinco Pharmaceuticals Searching for New Auditor Following EY's Resignation	22-12-08	MT
Sinco Pharmaceuticals Unit, Beijing Nuokangda Sign Agreements for Facial Needle Development	22-11-08	MT
Sinco Pharmaceuticals Holdings Limited Enters into the Secret Needle Technological Development Agreements with Beijing Nuokangda	22-11-07	CI
Sinco Pharmaceuticals Holdings Limited(SEHK:6833) added to S&P Global BMI Index	22-09-19	CI
Sinco Pharmaceuticals' H1 Profit Down on Higher Selling Costs	22-08-31	MT
Sinco Pharmaceuticals Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI

Chart Sinco Pharmaceuticals Holdings Limited

Duration

Period

Chart Sinco Pharmaceuticals Holdings Limited

More charts

Company Profile

Sinco Pharmaceuticals Holdings Limited operates as one provider of marketing, promotion and channel management (MPCM) services in the People's Republic of China (PRC) pharmaceutical industry. It provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
SINCO PHARMACEUTICALS HOLDINGS LIMITED	-1.25%	61.75M
MCKESSON CORPORATION	+20.04%	72.24B
CARDINAL HEALTH, INC.	-2.10%	24.04B
SINOPHARM GROUP CO. LTD.	+6.85%	8.92B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+10.34%	8.58B
HUADONG MEDICINE CO., LTD	-19.68%	8.07B
H. LUNDBECK A/S	+13.68%	5.24B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+14.69%	4.24B
EBOS GROUP LIMITED	-1.04%	4.15B
GALENICA AG	-2.27%	3.92B

Pharmaceuticals Wholesale